[PDF][PDF] No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma …
M Guida, N Bartolomeo, P Quaglino, G Madonna… - 2021 - usiena-air.unisi.it
M Guida, N Bartolomeo, P Quaglino, G Madonna, J Pigozzo, AM Di Giacomo, AM Minisini…
2021•usiena-air.unisi.itAims: It is debated whether the NRAS-mutant melanoma is more aggressive than NRAS
wildtype. It is equally controversial whether NRAS-mutant metastatic melanoma (MM) is
more responsive to checkpoint inhibitor immunotherapy (CII). 331 patients treated with CII as
first-line were retrospectively recruited: 162 NRAS-mutant/BRAF wild-type (mut/wt) and 169
wt/wt. We
wildtype. It is equally controversial whether NRAS-mutant metastatic melanoma (MM) is
more responsive to checkpoint inhibitor immunotherapy (CII). 331 patients treated with CII as
first-line were retrospectively recruited: 162 NRAS-mutant/BRAF wild-type (mut/wt) and 169
wt/wt. We
Abstract
Aims: It is debated whether the NRAS-mutant melanoma is more aggressive than NRAS wildtype. It is equally controversial whether NRAS-mutant metastatic melanoma (MM) is more responsive to checkpoint inhibitor immunotherapy (CII). 331 patients treated with CII as first-line were retrospectively recruited: 162 NRAS-mutant/BRAF wild-type (mut/wt) and 169 wt/wt. We
usiena-air.unisi.it